Healthcare Value Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$4.19M Sell
60,000
-15,000
-20% -$1.05M 8.27% 1
2021
Q2
$5.17M Hold
75,000
10.29% 1
2021
Q1
$4.85M Buy
75,000
+25,000
+50% +$1.61M 10.8% 1
2020
Q4
$2.91M Hold
50,000
9.81% 4
2020
Q3
$3.16M Hold
50,000
10.41% 3
2020
Q2
$3.85M Hold
50,000
9.82% 2
2020
Q1
$3.74M Sell
50,000
-20,000
-29% -$1.38M 6.29% 4
2019
Q4
$4.55M Hold
70,000
13.39% 2
2019
Q3
$4.44M Hold
70,000
8.01% 2
2019
Q2
$4.73M Buy
70,000
+20,000
+40% +$1.32M 8.87% 4
2019
Q1
$3.25M Buy
+50,000
New +$3.32M 12.53% 4
2018
Q4
Sell
-100,000
Closed -$7.72M 12
2018
Q3
$7.72M Hold
100,000
18.67% 1
2018
Q2
$7.08M Hold
100,000
20.08% 1
2018
Q1
$7.54M Buy
100,000
+25,000
+33% +$1.99M 31.33% 1
2017
Q4
$5.37M Hold
75,000
16.34% 2
2017
Q3
$6.08M Hold
75,000
12.16% 4
2017
Q2
$5.31M Hold
75,000
9.54% 4
2017
Q1
$5.09M Hold
75,000
8.71% 4
2016
Q4
$5.37M Buy
75,000
+50,000
+200% +$3.72M 5.75% 7
2016
Q3
$1.98M Buy
+25,000
New +$2.03M 3.13% 11

Other funds holding GILD

Healthcare Value Capital's GILD Position: Q3 2021 in Review

Healthcare Value Capital reduced its Gilead Sciences (GILD) stake by 20% in Q3 2021, selling an estimated $1.05M and leaving 60,000 shares worth $4.19M. The position accounts for 8.27% of the portfolio, ranked #1.

Healthcare Value Capital first reported a position in GILD in Q3 2016 and has held it in 20 quarters since. The position peaked at $7.72M in Q3 2018. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

  • Healthcare Value Capital held 60,000 shares of Gilead Sciences worth $4.19M as of Q3 2021.
  • Healthcare Value Capital sold 15,000 Gilead Sciences shares in Q3 2021, an estimated $1.05M.
  • Gilead Sciences made up 8.27% of Healthcare Value Capital's portfolio in Q3 2021, its #1 holding.
  • Healthcare Value Capital first reported a position in Gilead Sciences in Q3 2016 and has held it in 20 quarters since.
  • Healthcare Value Capital's Gilead Sciences position peaked at $7.72M in Q3 2018.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Healthcare Value Capital's 13F filing for Q3 2021, filed 15 Nov 2021.